Rabeprazole Sodium DR
ID: SPE2D2-25-R-0006Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/69c1c0b64e614d89a5039b6963728763/view
Timeline
  1. 1
    Posted Apr 15, 2025, 12:00 AM UTC
  2. 2
    Updated Apr 15, 2025, 12:00 AM UTC
  3. 3
    Due May 15, 2025, 7:00 PM UTC
Description

The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Rabeprazole Sodium DR 20MG Tablets. This procurement aims to fulfill the pharmaceutical needs of military personnel, emphasizing compliance with federal acquisition regulations and ethical conduct in contractor performance. Interested vendors must submit their proposals via the DLA's Internet Bid Board System (DIBBS) by May 15, 2025, and are encouraged to reach out to primary contact Trong Nguyen at Trong.Nguyen@dla.mil or secondary contact Jason Wray at jason.wray@dla.mil for further inquiries.

Files
Title
Posted
SPE2D2-25-R-0006 Solicitation - Rabeprazole Final.pdf
Apr 15, 2025, 7:06 PM UTC
The document, Solicitation No. SPE2D2-25-R-0006, outlines requirements for submitting proposals for pharmaceutical products to the Defense Logistics Agency (DLA). The solicitation specifies a due date of May 15, 2025, and mandates submission exclusively through the DLA's Internet Bid Board System (DIBBS). It includes details about contractor requirements, such as providing a Subcontracting Plan for large businesses and adhering to specific regulations, including the Contractor Code of Business Ethics and Conditions for compliance with federal laws. The supply items listed primarily focus on various quantities of Rabeprazole DR 20MG Tablets, with additional specifications for contract performance and delivery. There are clauses included that address terms related to ethical conduct, reporting, and contractor performance assessments. Significant emphasis is put on compliance with multiple federal acquisition regulations (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS) clauses, particularly regarding telecommunications equipment. The document ultimately serves to guide potential offerors in complying with legal and operational requirements while bidding for government contracts in the pharmaceutical supply sector.
Lifecycle
Title
Type
Rabeprazole Sodium DR
Currently viewing
Solicitation
Rabeprazole Sodium DR
Presolicitation
Similar Opportunities
Rabeprazole Sodium Delayed Release Tablets
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
Pantoprazole DR Tablets
Buyer not available
Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
Budesonide ER Capsules
Buyer not available
The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Budesonide ER 3MG Capsules, as outlined in Solicitation No. SPE2D225R0008. This solicitation requires electronic submission of offers via the Defense Logistics Agency Internet Bid Board System (DIBBS) and includes a comprehensive Statement of Work detailing contract obligations such as delivery schedules, product registration, and compliance with federal acquisition regulations. The procurement of these pharmaceutical products is critical for supporting military health needs, ensuring that service members have access to necessary medications. Interested vendors should direct inquiries to Christopher Newman at christopher.newman@dla.mil or Jason Wray at jason.wray@dla.mil, with proposals due by the specified deadline in the solicitation document.
Pyridostigmine Bromide Tablets
Buyer not available
The Defense Logistics Agency (DLA) Troop Support is seeking sources capable of providing Pyridostigmine Bromide Tablets (PB Tabs), specifically the USP 30 MG formulation, in compliance with FDA specifications. The procurement involves an estimated annual requirement of 27,000 packages, with each package containing 210 individually sealed tablets, and deliveries will be made to the Defense Distribution Center in Norfolk, VA. Pyridostigmine Bromide Tablets are critical for military use, and the contract will include a base year with four one-year option periods, allowing for adjustments based on service requirements. Interested vendors should submit their responses electronically to Contracting Specialist Rosbert Jones at rosbert.jones@dla.mil, ensuring all information remains confidential as per federal regulations.
Dextroamphetamine - Amphetamine ER
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Dextroamphetamine - Amphetamine ER Capsules, specifically in dosages of 5 MG, 10 MG, 15 MG, 20 MG, 25 MG, and 30 MG, packaged in 100 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Bureau of Prisons, and Indian Health Service customers through DLA and VA prime vendor programs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be solicited as a commercial item under FAR part 12. Interested parties should monitor the DLA Bid Board System (DIBBS) and SAM.gov for the solicitation, projected for April 2025, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil.
Dimethyl Fumarate DR Presolicitation
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
Fluconazole Tablets
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Fluconazole Tablets, which are essential pharmaceuticals used in various medical treatments. The procurement will include multiple formulations of Fluconazole, specifically 50 MG, 100 MG, 200 MG tablets in various counts, and 150 MG tablets in unit dose packs, aimed at supporting the Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base and four one-year options, with the solicitation expected to be posted in April 2024. Interested parties should direct inquiries to Courtney Hunter-Stangler at Courtney.Hunter-Stangler@dla.mil and are encouraged to monitor the DLA Bid Board System and SAM.gov for updates.
Solifenacin
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Solifenacin, specifically 5MG and 10MG tablets in 30 and 90 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Indian Health Service, and Bureau of Prisons through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should direct inquiries to Jayne Do at jayne.do@dla.mil, with the solicitation anticipated to be posted in April 2025 on the DLA Bid Board System and SAM.gov.
Famotidine
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
Repaglinide
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.